Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

about

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Item

http://www.wikidata.org/entity/Q47962680

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@en

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@nl

type

Item

label

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@en

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@nl

prefLabel

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@en

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@nl

P1476

Long-term systemic lupus eryth ...... c bone marrow transplantation.

@en

P2093

A E Dezern

http://www.w3.org/2001/XMLSchema#string

D E Gladstone

http://www.w3.org/2001/XMLSchema#string

D Fine

http://www.w3.org/2001/XMLSchema#string

J Bolaños-Meade

http://www.w3.org/2001/XMLSchema#string

R A Brodsky

http://www.w3.org/2001/XMLSchema#string

R J Jones

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial

Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplan

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

P304

773-776

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203316669242

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michelle A. Petri

P577

2016-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27687020

http://www.w3.org/2001/XMLSchema#string

P932

5374037

http://www.w3.org/2001/XMLSchema#string